Approval of Biosimilar Hyrimoz™ (adalimumab-adaz)
This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The RheumatoidArthritis.net team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
- FDA Approves Sandoz’s Biosimilar Adalimumab, Hyrimoz. The Center for Biosimilars. Available at https://www.centerforbiosimilars.com/news/fda-approves-sandozs-biosimilar-adalimumab-hyrimoz. Accessed 11/2/18.
- Sandoz receives US FDA approval for biosimilar Hyrimoz(TM) (adalimumab-adaz). Novartis. Available at https://www.novartis.com/news/media-releases/sandoz-receives-us-fda-approval-biosimilar-hyrimoztm-adalimumab-adaz. Accessed 11/2/18.
- Biologics and biosimilars. PhRMA. Available at https://www.phrma.org/advocacy/research-development/biologics-biosimilars. Accessed 11/2/18.
- Biosimilars. U.S. Food and Drug Administration. Available at https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/default.htm. Accessed 11/2/18.